



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – Drug Update: Shortage of Trastuzumab (HERCEPTIN®); New Program: Addition of Carboplatin and Paclitaxel to Radiotherapy for Cervical Cancer; Highlights of Changes in Protocols and PPOs: Use of In-Line Filter for Etoposide Administration; Change in Terminology from Non-PVC to Non-DEHP
- **Provincial Systemic Therapy Program** – New Policy: Accessing Non-Benefit Cancer Drugs at BCCA Centres; Revised Policy: Extravasation Management
- **Benefit Drug List** – Adjuvant Treatment of Cervical Cancer with Carboplatin and Paclitaxel
- **Cancer Drug Manual** – Revised: Rituximab
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: SAVDCM; Revised: BRAJACTG, BRAJACTT, BRAJACTTG, BRAJDCARBT, BRAJDTFEC, BRAJFEC, BRAJFEC, BRAJFEC, BRAJFEC, BRAJFEC, BRAJTDC, GIAVCETIR, GIGAJCC, LYCCOP, SAVAC; Use of In-Line Filter for Etoposide Administration: CNCARV, GIPE, GOBEP, GOEP, GOOVETO, GOSMCCRT, GUBEP, GUEP, GUSCPE, GUSCPERT, GUVIP2, HLHETCSPA, HNAVPE, HNNAVPE, LULAPERT, LUOTPE, LUOTPERT, LUPUPE, LUSCPE, LUSCPERT, LYABVD, LYCHOP, LYCHOPR, LYCVPPABO, LYIVACR, LYPALL, ULYRICE, PUCAT, SAAVGEMD, SAIME
- **Website Resources and Contact Information**

EDITOR'S CHOICE

DRUG UPDATE

Shortage of Trastuzumab (HERCEPTIN®) and Temporary Access to US Supply – A shortage of Canadian-labelled trastuzumab (HERCEPTIN®) 440 mg vials is expected in Canada starting on 15 August and continuing until 6 October due to temporary constraints in production capacity by the manufacturer. This does not affect the supply produced for the US market. Therefore, hospitals can continue to deliver trastuzumab therapy by requesting supplies of the US-labelled version of trastuzumab via Health Canada's Special Access Programme (SAP) on a case-by-case basis.

SAP will accept requests prior to 15 August but decisions will be notified effective 15 August. Requests should be faxed in the usual manner and every effort is made by SAP to process them within 24 hours of receipt effective 15 August. Once a Letter of Authorization is issued to the manufacturer and copied to the requesting physician, the shipping process from the manufacturer to the requester should be within 1 business day. Existing supply may be transferred to new patients, provided a new SAP request and authorization has been obtained.

EDITOR'S CHOICE

The SAP does not require specific log on usage. Therefore, individual institutions can decide on the most efficient way for record keeping. There are no special reporting requirements beyond normal regulatory reporting of adverse or unexpected patient outcomes.

The following are tips on completing the SAP request:

- **Section A:** Physicians may request for individual patients. Institutions may also submit one request for multiple patients under the signature of one physician as long as the required patient information for *each* patient is provided. The request can include both patients currently on trastuzumab therapy and patients expected to receive the therapy during the 7-week shortage.
- **Section C:** If a request is for more than 4 patients, a table can be appended listing the patients and detailing the required information for each patient:
 - Patient initials, date of birth, gender
 - Indications, new or repeat patients via SAP
 - Dosage and duration, strength, quantity (the total amount required per patient during the 7-week shortage period)

The patients may be grouped by indication under separate tables (e.g., “Table 1. Early breast cancer”, “Table 2. Metastatic breast cancer”, “Table 3. Gastric cancer”).

- **Section D:** clinical rationales that align with the Canadian product monograph include:
 - *Adjuvant treatment of HER2 +ve early breast cancer in combination with chemotherapy and after chemotherapy*
 - *Treatment of HER2 +ve metastatic breast cancer*
 - *Treatment of HER2 +ve metastatic adenocarcinoma of the stomach (or GE junction) in combination with chemotherapy and after chemotherapy*

The Canadian product monograph of HERCEPTIN® can be cited as the supporting evidence for these indications. An overall clinical rationale may be provided for multiple patients (e.g., all patients treated for HER2 +ve metastatic breast cancer, etc.). If the request is for patients with different indications, it can refer to the appended tables, e.g.

- Table 1 lists patients with early breast cancer
- Table 2 lists patients with metastatic breast cancer
- Table 3 lists patients with gastric cancer

The BCCA has available the suggested templates for the three main indications which can be completed by the individual institution with the patient information. These are posted on the BCCA website with this issue of the Systemic Therapy Update (www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate)

The product authorized under the SAP will be the US- labelled stock (lot no. L592113, expiry December 2015). The vial has a blue plastic flip-off cap rather than the green cap of the Canadian vial. The diluent type and volume is the same but the diluent is supplied in a larger vial (30 mL, with white plastic flip-off cap) than the Canadian diluent.

NEW PROGRAM

The Provincial Systemic Therapy Program has approved the following program effective 01 August 2014:

Addition of Carboplatin and Paclitaxel to Radiotherapy for Cervical Adenocarcinoma (GOXAJCAT) – In a phase III trial involving 880 patients, the addition of platinum and paclitaxel to radiotherapy was associated with improved disease free survival (70% vs. 50%) in women with advanced cervical carcinoma (*Tang et al. Gynecol Oncol 2012*)

HIGHLIGHTS OF CHANGES IN PROTOCOLS AND PPPOs

Use of In-Line Filter for Etoposide Administration – Etoposide after dilution for parenteral administration has the potential to precipitate because its stability depends on the concentration of the drug. Because precipitation is difficult to predict, routine use of an in-line filter is recommended. This information has been updated in all etoposide-containing chemotherapy protocols and PPPOs (see [below](#)).

Changes in Terminology from Non-PVC to Non-DEHP – BCCA chemotherapy protocols and pre-printed orders have been revised to indicate that equipment (e.g. IV tubings and bags) which contains no diethylhexyl phthalate (DEHP) is appropriate for use with drugs that require non-polyvinyl chloride (PVC) equipment.

Traditionally, PVC equipment contains DEHP, a plasticizer used to increase product pliability and kink resistance. However, DEHP may be hepatotoxic and carcinogenic, and as well may cause reproductive and developmental toxicities. It can also leach out of PVC by reacting with some excipients that make drugs more soluble, such as Cremophor EL (paclitaxel, teniposide) and polysorbate 80 (carbazitaxel, docetaxel, etoposide, temsirolimus). Therefore, these drugs are routinely prepared and administered using non-PVC equipment.

Recently, PVC equipment using other plasticizers has become available. These plasticizers (e.g. trioctyltrimellitate [TOTM]) are less toxic and less likely to leach from PVC equipment.¹ Therefore, the terms “non-PVC” and “non-DEHP” can no longer be used interchangeably. The term “non-DEHP” has replaced “non-PVC” in the affected Cancer Drug Manual monographs (see [July 2014](#) issue of the Systemic Therapy Update), chemotherapy protocols and PPPOs (see [below](#)).

References:

1. Scientific Committee on Emerging and Newly-Identified Health Risks (SCENIHR). Opinion on the safety of medical devices containing DEHP-plasticized PVC or other plasticizers on neonates and other groups possibly at risk. Brussels, Belgium: European Commission; 2008

PROVINCIAL SYSTEMIC THERAPY PROGRAM

NEW BCCA POLICY – ACCESSING NON-BENEFIT CANCER DRUGS AT BCCA CENTRES

The new BCCA Systemic Therapy Policy ([III-130](#)) provides BCCA centres with a consistent approach to the purchasing, preparation, dispensing and administration of non-benefit cancer drugs. As there is already limited resources to deliver benefit drug treatments, BCCA centres do not dispense and/or administer anti-cancer drugs that are not on the [Benefit Drug List](#) even though they may have regulatory approval in Canada. Other non-benefit drugs may be accessed via community pharmacies and/or private infusion centres.

Please note that this policy is intended for BCCA centres. Communities Oncology Network centres may have their own internal policies to govern the access and delivery of non-benefit drugs.

PROVINCIAL SYSTEMIC THERAPY PROGRAM

REVISED BCCA POLICY – PREVENTION AND MANAGEMENT OF CHEMOTHERAPY EXTRAVASATION

BCCA Systemic Therapy Policy [III-20](#) has been updated to include new benefit drugs:

Extravasation Hazard	
Irritant	None
Arsenic Bendamustine Trastuzumab Emtansine (KADCYLA®)	Brentuximab Cabazitaxel Eribulin Ipilimumab Pertuzumab

BENEFIT DRUG LIST

NEW PROGRAMS

The following programs has been added to the [Benefit Drug List](#) effective 01 August 2014:

Protocol Title	Protocol Code	Benefit Status
Primary Adjuvant Treatment of Adenocarcinoma/Adenosquamous Cancer of the Cervix with CARBOplatin and PACLitaxel Prior to Irradiation with or without CISplatin	GOXAJCAT	Class I

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Rituximab Monograph:

- *Caution section* – revised hepatitis screening recommendations to be consistent with protocols and PPPOs now extended to all patients (not just those at high risk)

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):				
CODE	Protocol	PPPO	Patient Handout	Protocol Title
GOCXAJCAT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Primary Adjuvant Treatment of Adenocarcinoma/Adenosquamous Cancer of the Cervix with CARBOplatin and PACLitaxel Prior to Irradiation with or without CISplatin
SAVDCM	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adjuvant Therapy for Rhabdomyosarcoma using vinCRISTine, Dactinomycin, Cyclophosphamide and Mesna

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJACTG	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section clarified, filgrastim teaching added</i>	Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel
BRAJACTT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section clarified</i>	Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab
BRAJACTTG	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section clarified, filgrastim teaching added</i>	Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab
BRAJDCARBT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section clarified</i>	Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab
BRAJDTFEC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Trastuzumab cycle 1 treatment clarified</i>	Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Trastuzumab, and Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFECD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Lab tests for cycle 4 clarified</i>	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BRAJFECDT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section clarified</i>	Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide Followed by DOCEtaxel and Trastuzumab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJFECDT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Lab tests for cycle 4 clarified</i>	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide Followed by DOCEtaxel and Trastuzumab (HERCEPTIN)
BRAJTDC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return Appointment section clarified</i>	Adjuvant Therapy for Breast Cancer using Trastuzumab, DOCEtaxel and Cyclophosphamide
GIAVCETIR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Post-infusion observation clarified</i>	Third Line Treatment of Metastatic Colorectal Cancer using Cetuximab in Combination with Irinotecan
GIGAJCC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility exclusions clarified</i>	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation, using CISplatin and Capecitabine
LYCCOP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>vinCRISTine administration clarified</i>	Treatment of Hodgkin's disease using Cyclophosphamide, vinCRISTine, predniSONE
SAVAC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Protocol: minor typo corrected; PPPO: cyclophosphamide infusion duration, Return Appointment section and vinCRISTine dose modifications clarified</i>	Adjuvant Therapy for Newly Diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumor (PNET) or Rhabdomyosarcoma using vinCRISTine, DOXOrubicin and Cyclophosphamide

Protocols and PPPOs of the following etoposide-containing regimens have been revised to include the use of in-line filter for potential particulate precipitation.

CODE	Protocol Title
CNCARV	CARBOplatin and Etoposide in the Treatment of Recurrent Ependymoma
CNIME	Ifosfamide, Mesna and Etoposide in the Treatment of Recurrent Brain Tumours
GIPE	Palliative Therapy of Neuroendocrine Tumours using CISplatin and Etoposide
GOBEP	Therapy of Non-Dysgerminomatous Ovarian Germ Cell Cancer using Bleomycin, Etoposide and CISplatin
GOEP	Therapy of Dysgerminomatous Ovarian Germ Cell Cancer using CISplatin and Etoposide
GOOVETO	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma using Etoposide
GOSMCCRT	Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using PACLitaxel, CISplatin, Etoposide and CARBOplatin with Radiation
GUBEP	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin

CODE	Protocol Title
GUEP	Therapy for Nonseminoma Germ Cell Cancer using Etoposide-CISplatin
GUSCPE	Palliative Therapy of Extensive Stage Genitourinary Small Cell Tumours with a Platinum and Etoposide
GUSCPERT	Therapy of Genitourinary Small Cell Tumors with a Platin and Etoposide with Radiation
GUVIP2*	Nonseminoma Consolidation/Salvage Protocol using Etoposide, CISplatin, Ifosfamide and Mesna
HLHETCSPA	Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and cycloSPORINE
HNAVPE	Treatment of Recurrent and Metastatic Squamous Cell Cancer with Platinum and Etoposide
HNNAVPE	Treatment of Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Etoposide
LULAPERT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using CISplatin and Etoposide with Radiation Therapy
LUOTPE	Treatment of Thymoma with CISplatin and Etoposide
LUOTPERT	Treatment of Thymoma using CISplatin and Etoposide with Radiation Therapy
LUPUPE	Treatment of Cancer of Unknown Primary Involving the Thorax with CISplatin and Etoposide
LUSCPE	Therapy of Extensive Stage Small Cell Lung Cancer with CISplatin and Etoposide
LUSCPERT	Therapy of Limited Stage Small Cell Lung Cancer using Cisplatin And Etoposide with Radiation
LYABVD	Treatment of Hodgkin's disease with DOXOrubicin, Bleomycin, vinBLAStine and Dacarbazine
LYCHOP	Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISStine and predniSONE
LYCHOPR	Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISStine, predniSONE and riTUXImab
LYCVPPABO	Treatment of Hodgkin's Disease with Cyclophosphamide, vinBLAStine, Procarbazine and predniSONE
LYIVACR	Treatment of Burkitt's Lymphoma and Leukemia with Ifosfamide, Mesna, Etoposide, Cytarabine and riTUXImab
LYPALL*	Lymphoma Palliative Chemotherapy
ULYRICE	Treatment of Advanced Stage Large B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXImab
SAIME	Etoposide, Ifosfamide-Mesna for Patients with Newly Diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumour or Rhabdomyosarcoma or Advanced Soft Tissue or Bony Sarcomas

* Protocol only

The following chemotherapy protocols and PPPOs have been revised to replace the term “non-PVC” with “non-DEHP”.

CODE	Protocol Title
BRAJACT	Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel
BRAJACTG	Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide followed by PACLitaxel
BRAJACTT	Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab
BRAJACTTG	Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab
BRAJACTW	Adjuvant Therapy for Early Breast Cancer using DOXOrubicin and Cyclophosphamide followed by Weekly PACLitaxel
UBRAJDAC	Adjuvant Therapy for Breast Cancer using Cyclophosphamide, DOXOrubicin and DOCEtaxel
BRAJDC	Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Cyclophosphamide
BRAJDCARBT	Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab
BRAJDTFEC	Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Trastuzumab, and Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFECD	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BRAJFECDT	Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide Followed by DOCEtaxel and Trastuzumab
BRAJTDC	Adjuvant Therapy for Breast Cancer Using Trastuzumab, DOCEtaxel and Cyclophosphamide
BRAVABR	Palliative Therapy for Metastatic Breast Cancer using Nanoparticle, Albumin-Bound (nab)-PACLitaxel
BRAVDCAP	Palliative Therapy for Metastatic Breast Cancer using DOCEtaxel and Capecitabine
BRAVDOC	Palliative Therapy for Metastatic Breast Cancer using DOCEtaxel
BRAVDOC7	Palliative Therapy for Metastatic Breast Cancer using Weekly Docetaxel
BRAVGEMD	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and DOCEtaxel
BRAVGEMT	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and PACLitaxel
UBRAVPTRAD	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer
BRAVT7	Palliative Therapy for Metastatic Breast Cancer using Weekly PACLitaxel
BRAVTAX	Palliative Therapy for Metastatic Breast Cancer using PACLitaxel
BRAVTPCARB	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer
BRAVTRAD	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer

CODE	Protocol Title
BRAVTRAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and PACLitaxel as First-Line Treatment for Advanced Breast Cancer
BRLAACD	Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide Followed by DOCETaxel
BRLAACDT	Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide Followed by DOCETaxel and Trastuzumab
BRLAACTW	Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide Followed by Weekly PACLitaxel
CNCARV	CARBOplatin and Etoposide in the Treatment of Recurrent Ependymoma
CNIME	Ifosfamide, Mesna and Etoposide in the Treatment of Recurrent Brain Tumours
GIENACTRT	Neoadjuvant Treatment of Esophageal and Gastroesophageal Carcinomas Using CARBOplatin, PACLitaxel and Radiation Therapy
GIPE	Palliative Therapy of Neuroendocrine Tumours using CISplatin and Etoposide
GOBEP	Therapy of Non-Dysgerminomatous Ovarian Germ Cell Cancer using Bleomycin, Etoposide and CISplatin
GOCXCAD	Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with CARBOplatin and DOCETaxel in Ambulatory Care Settings
GOCXCAT	Primary Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with CARBOplatin and PACLitaxel in Ambulatory Care Settings
UGOCXCATB	Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel
GOENDCAD	Treatment of Primary Advanced or Recurrent Endometrial Cancer using CARBOplatin and DOCETaxel
GOENDCAT	Treatment of Primary Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel
GOEP	Therapy of Dysgerminomatous Ovarian Germ Cell Cancer Using CISplatin and Etoposide
GOOVCADM	Primary Treatment of Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer, with No Visible Residual Tumour (Moderate-High Risk) using CARBOplatin and DOCETaxel
GOOVCADR	Second Line Treatment using DOCETaxel and CARBOplatin for Epithelial Ovarian Cancer Relapsing after Primary Treatment
GOOVCADX	Primary Treatment of Visible Residual (Extreme Risk) Invasive Epithelial Ovarian Cancer using CARBOplatin and DOCETaxel
GOOVCATM	Primary Treatment of Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer, with No Visible Residual Tumour (Moderate-High Risk) using CARBOplatin and PACLitaxel
GOOVCATR	Second Line Treatment using PACLitaxel and CARBOplatin for Epithelial Ovarian Cancer Relapsing After Primary Treatment
GOOVCATX	Primary Treatment of Visible Residual (Extreme Risk) Invasive Epithelial Ovarian Cancer in Ambulatory Care Settings using PACLitaxel and CARBOplatin
GOOVDDCAT	Treatment Of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma using CARBOplatin and Weekly PACLitaxel
GOOVDOC	Treatment Of Progressive, Platinum-Refractory Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma Or Fallopian Tube Carcinoma using DOCETaxel
GOOVETO	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma using Etoposide
GOOVI PPC	Primary Treatment of Stage III Less Than or Equal To 1 cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage I Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer using Intravenous and Intraperitoneal PACLitaxel and Intraperitoneal CARBOplatin

CODE	Protocol Title
GOOV TAX3	Treatment of Progressive, Platinum-Refractory Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma or Fallopian Tube Carcinoma using PACLitaxel
GOSADG	Treatment of Uterine Sarcoma Cancer using DOCEtaxel and Gemcitabine
GOSMCCRT	Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using PACLitaxel, CISplatin, Etoposide and CARBOplatin with Radiation
GUBEP	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin
GUEP	Therapy for Nonseminoma Germ Cell Cancer using Etoposide-CISplatin
UGUPCABA	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer using Cabazitaxel and predniSONE
GUPDOC	Palliative Therapy for Metastatic Hormone Refractory Prostate Cancer using DOCEtaxel
GUSCPE	Palliative Therapy of Extensive Stage Genitourinary Small Cell Tumours with a Platinum and Etoposide
GUSCPERT	Therapy of Genitourinary Small Cell Tumors with a Platin and Etoposide with Radiation
UGUTAXGEM	Palliative Therapy for Germ Cell Cancers using PACLitaxel and gemcitabine
UGUTEM	Therapy for Advanced Renal Cancer using Temsirolimus
UGUTIP*	Therapy for Relapsed Testicular Germ Cell Cancer using PACLitaxel, Ifosfamide and CISplatin
GUVIP2*	Nonseminoma Consolidation/Salvage Protocol using Etoposide, CISplatin, Ifosfamide and Mesna
HLHETCSPA	Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and cycloSPORINE
HNAVDOC	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with DOCEtaxel
HNAVDPD	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Platinum and DOCEtaxel
HNAVPE	Treatment of Recurrent and Metastatic Squamous Cell Cancer with Platinum and Etoposide
UHNLADCF	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with DOCEtaxel, CISplatin and Infusional Fluorouracil
UHNNAVPC	Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma with CARBOplatin and PACLitaxel
HNNAVPE	Treatment of Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Etoposide
LUAJPC	Adjuvant CARBOplatin and PACLitaxel Following Resection of stage I, II and IIIA Non-Small Cell Lung Cancer
LUAVDC	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with CISplatin and DOCEtaxel
LUAVDOC	Second-Line Treatment of Advanced Non-Small Cell Lung Cancer with DOCEtaxel
LUAVPC	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with CARBOplatin and PACLitaxel
LULAPERT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using CISplatin and Etoposide with Radiation Therapy

CODE	Protocol Title
LUOTPE	Treatment of Thymoma with CISplatin and Etoposide
LUOTPERT	Treatment of Thymoma using CISplatin and Etoposide with Radiation Therapy
LUPUPE	Treatment of Cancer of Unknown Primary Involving the Thorax with CISplatin and Etoposide
LUSCPE	Therapy of Extensive Stage Small Cell Lung Cancer with CISplatin and Etoposide
LUSCPERT	Therapy of Limited Stage Small Cell Lung Cancer using Cisplatin And Etoposide with Radiation
LYABVD	Treatment of Hodgkin's disease with DOXOrubicin, Bleomycin, vinBLAStine and Dacarbazine
LYCHOP	Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISStine and predniSONE
LYCHOPR	Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISStine, predniSONE and riTUXimab
LYCVPPABO	Treatment of Hodgkin's Disease with Cyclophosphamide, vinBLAStine, Procarbazine and predniSONE
LYIVACR	Treatment of Burkitt's Lymphoma and Leukemia with Ifosfamide, Mesna, Etoposide, Cytarabine and riTUXimab
LYPALL*	Lymphoma Palliative Chemotherapy
ULYRICE	Treatment of Advanced Stage Large B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXimab
PUCAT	Primary Treatment of Cancer of Unknown Primary Origin Using CARBOplatin and PACLitaxel
SAAVGEMD	Therapy for Soft Tissue Sarcomas using Gemcitabine and DOCEtaxel
SAIME	Etoposide, Ifosfamide-Mesna for Patients with Newly Diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumour or Rhabdomyosarcoma or Advanced Soft Tissue or Bony Sarcomas

* Protocol only

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 673028		sally.waignein@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN
 Rob Watt, BSc (Pharm)